Literature DB >> 11900586

Laboratory diagnosis of dysfibrinogenemia.

Mark T Cunningham1, John T Brandt, Michael Laposata, John D Olson.   

Abstract

Dysfibrinogenemia is a coagulation disorder caused by a variety of structural abnormalities in the fibrinogen molecule that result in abnormal fibrinogen function. It can be inherited or acquired. The inherited form is associated with increased risk of bleeding, thrombosis, or both in the same patient or family. Traditionally, dysfibrinogenemia is diagnosed by abnormal tests of fibrin clot formation; the thrombin time and reptilase time are the screening tests, and the fibrinogen clotting activity-antigen ratio is the confirmatory test. The inherited form is diagnosed by demonstrating similar laboratory test abnormalities in family members, and if necessary by analysis of the fibrinogen protein or fibrinogen genes in the patient. The acquired form is diagnosed by demonstrating abnormal liver function tests and by ruling out dysfibrinogenemia in family members. This article reviews the laboratory testing of dysfibrinogenemia and presents an algorithm for sequential test selection that can be used for diagnosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11900586     DOI: 10.5858/2002-126-0499-LDOD

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  19 in total

1.  Severe bleeding in a woman heterozygous for the fibrinogen gammaR275C mutation.

Authors:  Chantelle M Rein; Brian L Anderson; Morgan M Ballard; Christopher M Domes; Joshua M Johnston; Russell Jared Madsen; Kathryn K M Wolper; Andrew S Terker; John M Strother; Thomas G Deloughery; David H Farrell
Journal:  Blood Coagul Fibrinolysis       Date:  2010-07       Impact factor: 1.276

2.  Dysfibrinogenemia with Subgaleal Hematoma: An Unusual Presentation.

Authors:  Manika Khare; Vijay Kumar; Sadhna Marwah; A S Nigam; Gurdeep Buxi
Journal:  Indian J Hematol Blood Transfus       Date:  2015-10-26       Impact factor: 0.900

Review 3.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

4.  Management of dysfibrinogenemia in pregnancy: A case report.

Authors:  Jie Yan; Donghong Deng; Peng Cheng; Lin Liao; Meiling Luo; Faquan Lin
Journal:  J Clin Lab Anal       Date:  2017-09-26       Impact factor: 2.352

5.  Combined use of Clauss and prothrombin time-derived methods for determining fibrinogen concentrations: Screening for congenital dysfibrinogenemia.

Authors:  Liqun Xiang; Meiling Luo; Jie Yan; Lin Liao; Weijie Zhou; Xuelian Deng; Donghong Deng; Peng Cheng; Faquan Lin
Journal:  J Clin Lab Anal       Date:  2017-09-18       Impact factor: 2.352

6.  A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release.

Authors:  Jie Yan; Meiling Luo; Peng Cheng; Lin Liao; Xuelian Deng; Donghong Deng; Faquan Lin
Journal:  Int J Hematol       Date:  2016-12-08       Impact factor: 2.490

7.  Ventricular tachycardia in acute fulminant myocarditis: medical management and follow-up.

Authors:  J R Sharma; S Sathanandam; S P Rao; S Acharya; V Flood
Journal:  Pediatr Cardiol       Date:  2008-03       Impact factor: 1.655

Review 8.  Development and hemocompatibility testing of nitric oxide releasing polymers using a rabbit model of thrombogenicity.

Authors:  Terry C Major; Hitesh Handa; Gail M Annich; Robert H Bartlett
Journal:  J Biomater Appl       Date:  2014-06-16       Impact factor: 2.646

9.  Congenital fibrinogen disorders with repeated thrombosis.

Authors:  Xiuli Zhang; Chuang Zhang; Baoheng Wang; Ningheng Chen; Gaihe Sun; Xueli Guo
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

10.  A Double Whammy of Mycotic Aneurysms and Acquired Dysfibrinogenemia in a Patient with Septicemia.

Authors:  Chun Yang Sim; Ching Soong Khoo; Ruslinda Mustafar; Jia Ning Chai
Journal:  Balkan Med J       Date:  2021-01       Impact factor: 2.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.